This is truly an extraordinary time to be working in the field of immune cell engineering for treating human diseases! In this Research Topic, we invite submissions in CAR design, the development of ...

SARS-CoV-2 has an enzyme that can counteract a cell's innate defense mechanism against viruses, explaining why it is more ...

Dermatofibrosarcoma protuberans (DFSP) is a rare skin sarcoma known for its high recurrence rates, making treatment ...

Analysis - Breast cancer is the number one cancer among women: more than 2 million cases were diagnosed worldwide in 2022. It ...

Researchers at NYU Langone Health developed a new drug that targets mutant HER2 cancer proteins without harming healthy cells ...

Triple-negative breast cancer (TNBC): The breast tissue lacks estrogen receptors, progesterone receptors, and HER2 protein receptors that control how cells grow and divide. Triple-negative breast ...

A new study describes the development of a biologic, a drug derived from natural biological systems, that targets a mutant cancer protein called HER2 (human epidermal growth factor receptor 2) without ...

Live moderated webcast with Dr. Jim Bianco, President and Chief Executive Officer of TuHURA on Wednesday, October 30th ...

BriaCell Therapeutics could access a $1-$5 billion market upon approval despite a sub-$30 million cap. See more on BRIA stock ...

The company presented data showing that a single IV dose of its ctLNP delivered mRNA encoding a reporter protein to a ...

Touted by some as the answer to any and all energy and metabolism woes, this supplement could be a game-changer for the tired ...